drugset / Trial / NCT06132698
Immune Checkpoint Inhibitors Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single-arm, open clinical study, which was designed to evaluate the efficacy and safety of an immune checkpoint inhibitor combined with pemetrexed intrathecal injection in the treatment of patients with NSCLC associated with leptomeningeal metastases.
Timeline
- Start
- 2023-11-30
- Primary completion
- 2026-05-30
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 50 mg | — |
| Subject | Pemetrexed | Small molecule | 20 mg | Intrathecal |
| Subject | Tislelizumab | Monoclonal antibody | 50 mg | — |